3,5-bis(3,6-dimethoxycarbazol-9-yl)-4-[3-methyl-5-(trifluoromethyl)phenyl]benzonitrile
C43H32F3N3O4 — CID 134295566
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3,5-bis(3,6-dimethoxycarbazol-9-yl)-4-[3-methyl-5-(trifluoromethyl)phenyl]benzonitrile
3,5-bis(3,6-dimethoxycarbazol-9-yl)-4-[3-methyl-5-(trifluoromethyl)phenyl]benzonitrile (PubChem CID 134295566) has the molecular formula C43H32F3N3O4 and a molecular weight of 711.74 g/mol. Its IUPAC name is 3,5-bis(3,6-dimethoxycarbazol-9-yl)-4-[3-methyl-5-(trifluoromethyl)phenyl]benzonitrile.
Molecular Properties
| Compound Name | 3,5-bis(3,6-dimethoxycarbazol-9-yl)-4-[3-methyl-5-(trifluoromethyl)phenyl]benzonitrile |
|---|---|
| PubChem CID | 134295566 |
| Molecular Formula | C43H32F3N3O4 |
| Molecular Weight | 711.74 g/mol |
| Exact Mass | 711.23 |
| IUPAC Name | 3,5-bis(3,6-dimethoxycarbazol-9-yl)-4-[3-methyl-5-(trifluoromethyl)phenyl]benzonitrile |
| SMILES | COc1ccc2c(c1)c1cc(OC)ccc1n2-c1cc(C#N)cc(-n2c3ccc(OC)cc3c3cc(OC)ccc32)c1-c1cc(C)cc(C(F)(F)F)c1 |
| InChI | InChI=1S/C43H32F3N3O4/c1-24-14-26(18-27(15-24)43(44,45)46)42-40(48-36-10-6-28(50-2)19-32(36)33-20-29(51-3)7-11-37(33)48)16-25(23-47)17-41(42)49-38-12-8-30(52-4)21-34(38)35-22-31(53-5)9-13-39(35)49/h6-22H,1-5H3 |
| InChIKey | NHCMTBDGNHPTEW-UHFFFAOYSA-N |
| XLogP | 10.78 |
| TPSA | 70.57 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 7 |
| Rotatable Bonds | 7 |
| Heavy Atoms | 53 |
| Complexity | — |
Lipinski Rule of Five
2 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 711.74 |
| LogP ≤ 5 | 10.78 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 7 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 134295566 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.